Realizing the potential of antibody-drug conjugates

Antibody-drug conjugates (ADCs) have long been described as a promising component of the pharmaceutical industry’s oncology toolkit. Due to their exact nature, ADCs meet the growing demand for efficacious therapies that provide targeted and safer treatment options for cancer patients. However, even with a growing number of ADCs in the pipeline, the full promise of ADCs has yet to be fully realized.

Easy as ADC?
ADCs comprise three major components: a small molecule payload, a linker, and an antibody (see Figure 1). While this seems straightforward as a concept, in practice, designing, developing, and manufacturing ADCs is a complex and multi-faceted undertaking.